Roche (SIX: RO, ROG; OTCQX: RHHBY) gave an update on its strategy, which continues to be focused on medical innovation and sustainable growth. Through its leadership in personalised healthcare, Roche is uniquely positioned to develop therapies that advance current standards of care and improve people's lives.

New data for Lucentis® (ranibizumab), the only anti-VEGF therapy licensed across three ocular indications, show that individualized treatment with Lucentis provides sustained improvement in vision with a low number of injections.

Lilly Diabetes announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to use Glucagon for Injection, through simulated practice.

Novartis welcomed its annual International Biotechnology Leadership Camp (BioCamp), a three-day seminar bringing biotechnology and business experts together with 60 selected students from leading international universities in 21 countries and territories.

Boehringer Ingelheim has announced that the combined treatment experience with Pradaxa® has crossed one million patient-years(1) in the prevention of thromboembolic events in patients after surgery and in patients with non-valvular atrial fibrillation (AF), providing the greatest body of clinical experience among all novel oral anticoagulants.

GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease (COPD).

Roche and the Lucerne Festival are renewing their partnership in the Roche Commissions cultural programme. Since the programme was launched in 2003 Roche has commissioned an orchestral work from a renowned composer. Since 2006 the programme has taken place in a two-year cycle.